For over two centuries, Philadelphia has served as the crucible of American medicine. From the founding of the nation’s first hospital to the birth of modern dermatology, the city has consistently redefined how we understand the human body. Today, a new chapter in this legacy is being written by MyMonitor.Ai, a health-technology pioneer transforming dermatology from a field of subjective visual assessment into a quantifiable, data-driven science.
For decades, the gold standard in dermatology has relied on the human eye. However, clinical research reveals a persistent challenge in the form of inter-rater variability. A clinician’s experience, ambient lighting, and the patient’s skin tone can lead to inconsistent disease severity scoring. These discrepancies contribute to high placebo response rates and screen failures in clinical trials, particularly for inflammatory conditions like atopic dermatitis, psoriasis, and hidradenitis suppurativa.
Founded by CEO Charles Mbata and Co-Founder and CTO Seven Ezumba, MyMonitor.Ai was established to bridge this gap between clinical observation and objective data. With over 15 years of experience in clinical research, Mbata recognized that the lack of standardized endpoints was a primary bottleneck in drug development and patient equity. Alongside Ezumba, an architect of complex AI systems, they developed a platform that provides a governance layer for dermatological assessment, ensuring that what is seen on the skin is measured with mathematical precision.
A critical component of the company’s growth and technical validation is its strategic connection to the Temple University Innovation Nest, known as iNest. As part of this premier Philadelphia ecosystem for technology commercialization, MyMonitor.Ai leverages a robust network of academic expertise and research infrastructure. This partnership reinforces the company’s commitment to scientific rigor and provides a launchpad for scaling its innovations from the lab to global clinical environments.
At the heart of MyMonitor.Ai is a deterministic, melanin-aware AI overlay. Unlike traditional black-box artificial intelligence, which can be prone to algorithmic bias, MyMonitor.Ai utilizes a transparent feature-extraction pipeline. By integrating the Individual Typology Angle (ITA), which is a scientific standard for objective skin-tone quantification, the platform ensures that erythema and lesion morphology are assessed accurately across the entire Monk Skin Tone (MST) Scale. This approach directly addresses the historical underrepresentation of skin of color in clinical datasets and positions MyMonitor.Ai as a leader in medical equity.
The MyMonitor.Ai ecosystem is designed for the modern clinical environment, spanning dermatology clinics, decentralized clinical trials, and remote patient monitoring. The platform integrates seamlessly with a hardware roadmap that includes smart dermatoscopes and robotic imaging systems to ensure high-resolution, standardized image acquisition. By providing reproducible, quantitative metrics, such as reduced Mean Absolute Error (MAE) in longitudinal tracking, the system increases the statistical power of clinical trials and accelerates the delivery of life-saving therapeutics.
“Our architecture is built on the principle of human-in-the-loop intelligence,” explains Seven Ezumba. “We are not replacing the clinician’s judgment; rather, we are augmenting it with an auditable, explainable data layer that ensures consistency across different study sites and providers.”
As Philadelphia celebrates 250 years of innovation, MyMonitor.Ai stands as a testament to the city’s enduring leadership in healthcare. By combining clinical insight with deterministic engineering and the collaborative power of Temple University’s iNest, Mbata and Ezumba are doing more than building a platform: they are establishing a new global benchmark for how skin disease is measured, understood, and treated. In the city where American medicine began, MyMonitor.Ai is ensuring its future is objective, inclusive, and precise.
FACT: People with skin diseases Hidradenitis Suppurativa (HS) often see 5 or more physicians over 10 years before receiving a diagnosis, early detection and tracking is possible with MyMonitor. Diagnostic Delayin Hidradenitis Suppurativa: Still an Unsolved Problem. Dermatology. 2024;10(2):129–132. doi:10.1159/000534845
